Nivolumab for rare solid tumors with high PD-L1
Treatments studied
Part of Brain & nervous system, Cancer, Digestive system, Hormones & metabolism, Infections, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial is testing a drug called Nivolumab (an immunotherapy) for people with rare solid tumors that have high levels of PD-L1. It might be an option if you have tried other treatments and they stopped working or caused too many side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- A biopsy must show your tumor has a high level of PD-L1 (a protein linked to immune response).
- Your cancer is rare (a specific type listed in the trial) and has grown or you couldn't tolerate standard treatments.
- You must be in fairly good health (able to care for yourself and up and about more than half of your waking hours).
- If you or your partner could become pregnant, you must agree to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lower dose of nivolumab (an immunotherapy drug) given less frequently to treat cancers that have spread or cannot be surgically removed. The goal is to see if this approach works well while reducing side effects compared to standard dosing.
This trial tests a new drug called GV20-0251 combined with an immunotherapy called anti-PD-1, which helps your immune system fight cancer. The study focuses on advanced cancers that haven't responded to standard treatments or that you couldn't tolerate.
This trial tests a drug called ivonescimab in people with advanced, rare tumor types that have spread (stage IV). The goal is to see if the drug is safe and whether it can shrink tumors or slow their growth.
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
This trial studies nivolumab, an immune therapy, for skin squamous cell cancer that can’t be cured with surgery or radiation. It aims to see how well the treatment shrinks tumors and helps people live longer or longer without cancer growth.
Hear when a new Urachal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.